N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
We have completed patient enrollment in the the double blind, randomized, placebo-controlled
trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of
non-acetaminophen ALF. The purpose of this study is to examine the safety and efficacy of
intravenous NAC in children with ALF for whom no antidote or other specific treatment is
available. Inclusion in the NAC Study required enrollment in the Pediatric Acute Liver
Failure (PALF) Study Registry.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)